Related Experiment Video
Updated: Jul 23, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach
Seyedehsadaf Asfa1,2, Halil Ibrahim Toy1,2, Reza Arshinchi Bonab1,2
1Izmir Biomedicine and Genome Center (IBG), 35340 Izmir, Turkey.
Abstract:
Ewing sarcoma is a rare type of cancer that develops in the bones and soft tissues. Drug therapy represents an extensively used modality for the treatment of sarcomas. However, cancer cells tend to develop resistance to antineoplastic agents, thereby posing a major barrier in treatment effectiveness. Thus, there is a need to uncover the molecular mechanisms underlying chemoresistance in sarcomas and, hence, to enhance the anticancer treatment outcome. In this study, a differential gene expression analysis was conducted on high-throughput transcriptomic data of chemoresistant versus chemoresponsive Ewing sarcoma cells. By applying functional enrichment analysis and protein-protein interactions on the differentially expressed genes and their corresponding products, we uncovered genes with a hub role in drug resistance. Granted that non-coding RNA epigenetic regulators play a pivotal role in chemotherapy by targeting genes associated with drug response, we investigated the non-coding RNA molecules that potentially regulate the expression of the detected chemoresistance genes. Of particular importance, some chemoresistance-relevant genes were associated with the autonomic nervous system, suggesting the involvement of the latter in the drug response. The findings of this study could be taken into consideration in the clinical setting for the accurate assessment of drug response in sarcoma patients and the application of tailored therapeutic strategies.
Insights
This study identifies key genes and non-coding RNAs driving chemoresistance in Ewing sarcoma. Findings may improve drug response prediction and personalize sarcoma treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Ewing sarcoma is a rare bone and soft tissue cancer.
- Chemotherapy is a primary treatment, but drug resistance limits effectiveness.
- Understanding chemoresistance mechanisms is crucial for improving treatment outcomes.
Purpose of the Study:
- To identify molecular mechanisms of chemoresistance in Ewing sarcoma.
- To uncover novel therapeutic targets for overcoming drug resistance.
- To explore the role of non-coding RNAs and the autonomic nervous system in chemoresistance.
Main Methods:
- Differential gene expression analysis of transcriptomic data from chemoresistant and chemoresponsive Ewing sarcoma cells.
- Functional enrichment analysis and protein-protein interaction networks to identify hub genes.
- Investigation of non-coding RNA regulators targeting chemoresistance genes.
Main Results:
- Identified hub genes critical for Ewing sarcoma chemoresistance.
- Discovered non-coding RNAs potentially regulating chemoresistance-associated genes.
- Found associations between chemoresistance genes and the autonomic nervous system.
Conclusions:
- The study elucidates key molecular players in Ewing sarcoma chemoresistance.
- Findings suggest potential for novel therapeutic strategies targeting identified genes and RNAs.
- The autonomic nervous system's role in drug response warrants further investigation for clinical applications.
Related Concept Videos
Treatment Resistant Cancers
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

